Skip to Main Content

Author Details

Phillip G Febbo
Illumina Inc.
1997
103
45
Nathan Sheffield (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
34965953Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).Clin Cancer Res2022
33861950Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States.Cell2021
32766602High-throughput SARS-CoV-2 and host genome sequencing from single nasopharyngeal swabs.medRxiv2020
32017048Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases.Clin Pharmacol Ther2020
28988753A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.Eur Urol2018
30142405The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status.Urology2018
30033370Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.Cell2018
30288143Balancing Confounding and Generalizability Using Observational, Real-world Data: 17-gene Genomic Prostate Score Assay Effect on Active Surveillance.Rev Urol2018
30340047Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.Cell2018
29524506A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy.J Urol2018
29773662Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.Clin Cancer Res2018
29337486Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay.Am J Manag Care2018
28737972Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop.J Clin Oncol2017
28454985Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort.Urology2017
28187516Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium.Clin Pharmacol Ther2017
29472824Active Surveillance Use Among a Low-risk Prostate Cancer Population in a Large US Payer System: 17-Gene Genomic Prostate Score Versus Other Risk Stratification Methods.Rev Urol2017
29016610Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa).PLoS One2017
26723180Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score.Urology2016
27833462Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate Score.Rev Urol2016
27121323Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.Oncotarget2016
27143689Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.Clin Cancer Res2016
25465337A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.Eur Urol2015
37559290Utility of the Oncotype DX<sup>®</sup> Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A Retrospective Chart Review Analysis.Urol Pract2015
37559258The Impact of a Biopsy Based 17-Gene Genomic Prostate Score on Treatment Recommendations in Men with Newly Diagnosed Clinically Prostate Cancer Who are Candidates for Active Surveillance.Urol Pract2015
25635138Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.J Nucl Med2015
25795632In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?Oncologist2015
24366412Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy.Prostate Cancer Prostatic Dis2014
25548544A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer.Rev Urol2014
24836057A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.Eur Urol2014
23192356Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways.Prostate2013
29768744The current and future role of sequence-based analysis in prostate cancer treatment.Per Med2013
23925271Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success.Radiology2013
22088334Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center.J Urol2012
23034120Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity.Genome Biol2012
22461660Retraction in part: A genomic approach to identify molecular pathways associated with chemotherapy resistance.Mol Cancer Ther2012
22282219Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.Cancer2012
22340590An animal model of MYC-driven medulloblastoma.Cancer Cell2012
22393192Predictive biomarkers in advance of a companion drug: ahead of their time?J Natl Compr Canc Netw2012
22351745Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer.Mol Cancer Ther2012
21217686Retraction: Genomic signatures to guide the use of chemotherapeutics.Nat Med2011
22138009NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.J Natl Compr Canc Netw2011
22203777NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement.J Natl Compr Canc Netw2011
20026909MYC activity mitigates response to rapamycin in prostate cancer through 4EBP1-mediated inhibition of autophagy.Autophagy2010
20501622A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.Clin Cancer Res2010
20569070Immune signatures predict prognosis in localized cancer.Cancer Invest2010
19882268Cancer gene profiling in prostate cancer.Methods Mol Biol2010
19318631Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.J Natl Cancer Inst2009
19684076Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.Oncologist2009
19773438MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.Cancer Res2009
19362539A genomic strategy to elucidate modules of oncogenic pathway signaling networks.Mol Cell2009
  • 1 - 50 of 103

Recommended Authors

Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 11
Travis Gerke
The Prostate Cancer Clinical Trials Consortium
Career Start Year 2014
Number of shared co-authors 14
Nicholas Erho
GenomeDx Biosciences Inc.
Career Start Year 2012
Number of shared co-authors 26
Mandeep Takhar
GenomeDx Biosciences Inc.
Career Start Year 2010
Number of shared co-authors 21
Adam G Sowalsky
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 16
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 35
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 18
Mark M Pomerantz
Dana-Farber Cancer Institute
Career Start Year 2007
Number of shared co-authors 30
Elai Davicioni
Veracyte Inc.
Career Start Year 2006
Number of shared co-authors 46
Svitlana Tyekucheva
Dana-Farber Cancer Institute
Career Start Year 2006
Number of shared co-authors 6
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 50
Robert H Bell
University of British Columbia
Career Start Year 2004
Number of shared co-authors 16
Christopher E Barbieri
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 24
Charlie E Massie
University of Cambridge
Career Start Year 2003
Number of shared co-authors 3
Adam Sharp
The Institute for Cancer Research
Career Start Year 2003
Number of shared co-authors 15
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 33
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 19
Heather H Cheng
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 2002
Number of shared co-authors 35
Wassim Abida
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 33
Ilsa Coleman
Fred Hutchinson Cancer Center
Career Start Year 2001
Number of shared co-authors 42
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2001
Number of shared co-authors 41
Yuzhuo Wang
University of British Columbia
Career Start Year 2000
Number of shared co-authors 37
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 1
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 22
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Career Start Year 1997
Number of shared co-authors 36
Rosina T Lis
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 30
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 1990
Number of shared co-authors 34
Gyorgy Petrovics
Henry Jackson Foundation for the Advancement of Military Medicine (HJF)
Career Start Year 1990
Number of shared co-authors 13
Javed Siddiqui
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 1988
Number of shared co-authors 33
George Steven Bova
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1982
Number of shared co-authors 11

Collaborators

Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 15
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 14
Todd R Golub
Broad Institute of MIT and Harvard
Co-authored papers 8
Meir J Stampfer
Brigham and Women's Hospital
Co-authored papers 6
Adam Foye
University of California San Francisco
Co-authored papers 6
William R Sellers
Co-authored papers 6
Eric J Small
University of California san francisco
Co-authored papers 5
William K Oh
Co-authored papers 5
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Co-authored papers 5
Heather Gordish-Dressman
Co-authored papers 4
Edward L Giovannucci
Harvard T.H. Chan School of Public Health
Co-authored papers 4
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 4
Mark A Rubin
University of Bern
Co-authored papers 4
Geoffrey S Ginsburg
National Institutes of Health
Co-authored papers 4
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 3
Andrew Berchuck
Duke School of Medicine
Co-authored papers 3
Aaron R Thorner
Co-authored papers 3
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 3
Justin Guinney
University of Washington
Co-authored papers 3
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 3
Eric A Klein
Cleveland Clinic
Co-authored papers 3
Carey K Anders
Co-authored papers 3
Stephen J Freedland
Cedars-Sinai Medical Center
Co-authored papers 3
David H Harpole
Duke University Medical Center
Co-authored papers 3
Myles Brown
Co-authored papers 3
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 3
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Co-authored papers 3
Peter Kuhn
University of Tubingen
Co-authored papers 2
Lawrence Fong
University of California san francisco
Co-authored papers 2
Theodore C Goldstein
Bakar Computational Health Sciences Institute, University of California san francisco
Co-authored papers 2
Release 1.2